uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
复制标题
DOI:
10.18632/oncotarget.3680
复制
发表时间:
2015-06-10
期刊:
影响因子:
--
通讯作者:
Vahrmeijer AL
中科院分区:
文献类型:
--
作者:
Boonstra MC;van Driel PB;van Willigen DM;Stammes MA;Prevoo HA;Tummers QR;Mazar AP;Beekman FJ;Kuppen PJ;van de Velde CJ;Löwik CW;Frangioni JV;van Leeuwen FW;Sier CF;Vahrmeijer AL
Pre- and intraoperative diagnostic techniques facilitating tumor staging are of paramount importance in colorectal cancer surgery. The urokinase receptor (uPAR) plays an important role in the development of cancer, tumor invasion, angiogenesis, and metastasis and over-expression is found in the majority of carcinomas. This study aims to develop the first clinically relevant anti-uPAR antibody-based imaging agent that combines nuclear (111In) and real-time near-infrared (NIR) fluorescent imaging (ZW800-1). Conjugation and binding capacities were investigated and validated in vitro using spectrophotometry and cell-based assays. In vivo, three human colorectal xenograft models were used including an orthotopic peritoneal carcinomatosis model to image small tumors. Nuclear and NIR fluorescent signals showed clear tumor delineation between 24h and 72h post-injection, with highest tumor-to-background ratios of 5.0 ± 1.3 at 72h using fluorescence and 4.2 ± 0.1 at 24h with radioactivity. 1-2 mm sized tumors could be clearly recognized by their fluorescent rim. This study showed the feasibility of an uPAR-recognizing multimodal agent to visualize tumors during image-guided resections using NIR fluorescence, whereas its nuclear component assisted in the pre-operative non-invasive recognition of tumors using SPECT imaging. This strategy can assist in surgical planning and subsequent precision surgery to reduce the number of incomplete resections.